<DOC>
	<DOC>NCT01529541</DOC>
	<brief_summary>This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.</brief_summary>
	<brief_title>Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients who had diagnosed with type 2 DM before 3 months Men and women between the age of ≥ 19 and ≤ 75 years FPG ≤ 270 mg/dL at screening visit Patients who consent to participate in this trial by written Informed Consent Form Type 1 DM or secondary diabetes Subjects who are administrating oral antihyperglycemic drugs or have to take a medicine Body mass index &lt; 20 kg/m2 or &gt; 40.0kg/m2 Subjects who are assessed to be inappropriate for this trial by investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CWP-0403</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Metformin</keyword>
	<keyword>type 2 DM</keyword>
</DOC>